MedTrace Logo

A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects

NCT00334659 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2011-06-23

No results posted yet for this study

Summary

The purpose of this study is to confirm that apricitabine does not induce any clinically significant effect upon electrocardiogram (ECG) parameters at doses consistent with the maximum exposure expected to occur in clinical practice.

Conditions

  • HIV Infections

Interventions

DRUG

apricitabine

Sponsors & Collaborators

  • Avexa

    lead INDUSTRY

Principal Investigators

  • Susan W Cox, PhD · Avexa

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2006-08-31
Completion
2006-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00334659 on ClinicalTrials.gov